Клиномир в тестовом запуске. Кто с нами с первых дней, получит отметку «С первых дней» в профиле и первым увидит новые возможности сайта.

Зарегистрироваться
Завершено Фаза I–II Россия

SAR650984 (Изатуксимаб)

Исследование 1/2 фазы с эскалацией дозы по изучению безопасности, фармакокинетики и эффективности многократных внутривенных инфузий гуманизированных моноклональных антител (SAR650984) к CD38 у пациентов с CD38+ гемобластозами

Разрешение№ 8 от 13.01.2017
Номер протоколаTED 10893
ФазаФаза I–II
Участников по плану20
Сроки13.01.2017 — 31.12.2023
Страна разработчикаФранция
Начало: 13 января 2017Окончание: 31 декабря 2023
Плановый срок исследования истёк
Статус рассчитан по плановой дате окончания. В реестре указано: «Проводится».

Постоянная ссылка: https://clinomir.ru/trials/permit/ru/8/2017-01-13/

Источник: ГРЛС — Государственный реестр лекарственных средств Минздрава России; ClinicalTrials.gov (U.S. National Library of Medicine); Расчёт Клиномира. Что откуда

Простыми словами

Словарь терминов
  • Совмещённое исследование фаз Фаза I–II: Фаза I — первое применение у людей. Проверяют безопасность и подбирают дозу, участников немного. Фаза II — препарат уже прошёл первую проверку безопасности. Проверяют, действует ли он при этом заболевании, и уточняют дозу.
  • Исследование завершено, новых участников не набирают.
  • Возраст участников: от 18 лет. Остальные условия — в блоке «Кто может участвовать».
  • По плану участвуют 20 чел. в стране «Россия».
  • Центров в реестре: 4 в 4 городах. Список — ниже на странице.
  • Плановая дата окончания (12.2023) уже прошла.

Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.

Кто может участвовать

Возрастот 18 лет
ПолЛюбой
Здоровые добровольцынет

Главное из критериев

  • Предшествующее лечениене менее 3 линий терапии
  • Опухольнужен измеримый очаг (RECIST)

Выбрано из текста реестра автоматически, по правилам — без ИИ. Решение об участии принимает врач центра по полному протоколу.

Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 9 · невключение: 19

Критерии включения

  • Phase 1:
  • For dose escalation cohorts, participants with confirmed selected CD38+ hematological malignancies as specified below who had progressed on after standard therapy or for whom there was no effective standard therapy (refractory/relapsed participants). B-cell Non-Hodgkin-lymphoma/leukemia (NHL) participants with at least 1 measurable lesion. Multiple myeloma (MM) participants with measurable M-protein serum and/or 24-hour urine. Acute myeloid leukemia (AML) participants, all types except M3 based on French-American-British (FAB) classification. Acute Lymphoblastic Leukemia (B-cell ALL) participants. Chronic lymphocytic leukemia (CLL) participants.
  • For expansion cohorts, participants with relapsed/refractory MM with measurable M-protein (serum M-protein of >0.5 g/dL and/or urine M-protein of >200 mg (24-hr urine)) or elevated serum free light chains (FLC) >10 mg/dL with abnormal FLC ratio) who had progressed on or after standard therapy that included an Immunomodulatory drug (IMiD) and a proteasome inhibitor and who met the protocol defined criteria for standard risk or high risk.
  • Phase 2:
  • Participants had a known diagnosis of multiple myeloma with evidence of measurable disease, and have evidence of disease progression based on International Myeloma Working Group (IMWG) criteria: Serum M-protein ≥1 g/dL, or urine M-protein >=200 mg/24 hours or in the absence of measurable m-protein, serum FLC >=10 mg/dL, and abnormal serum immunoglobulin kappa lambda FLC ratio (<0.26 or >1.65).
  • Participants who received at least three prior lines of therapy for MM and had treatment with an IMiD (for >=2 cycles or >=2 months of treatment) and a proteasome inhibitor (PI) (for >=2 cycles or >=2 months of treatment) OR participants whose disease was double refractory to an IMiD and a PI. For participants who had received more than 1 type of IMiD and PI, their disease must be refractory to the most recent one.
  • Participants who had achieved a minimal response or better to at least one prior line of therapy.
  • Participants who had received an alkylating agent (>=2 cycles or >=2 months) either alone or in combination with other MM treatments.
  • Stage 2 only: Participants who had evidence of disease progression on or after the most recent prior regimen based on IMWG criteria.

Критерии невключения

  • Phase 1:
  • Karnofsky performance status <60
  • Poor bone marrow reserve
  • Poor organ function
  • Known intolerance to infused protein products, sucrose, histidine, polysorbate 80 or known hypersensitivity to any of the components of the study therapy that was not amenable to pre-medication with steroids and H2 blockers
  • Any serious active disease (including clinically significant infection that was chronic, recurrent, or active) or co-morbid condition, which, in the opinion of the investigator, interfered with the safety, the compliance with the study or with the interpretation of the results
  • Any severe underlying medical conditions including presence of laboratory abnormalities, which could impair the ability to participate in the study or the interpretation of its results
  • Phase 2:
  • Participants with multiple myeloma immunoglobulin M (IgM) subtype
  • Previous treatment with any anti-CD38 therapy
  • Participants with concurrent plasma cell leukemia
  • Participants with known or suspected amyloidosis
  • Karnofsky performance status <60 (stage 1)/Eastern Cooperative Oncology Group (ECOG) Performance status >2 (stage 2).
  • Poor bone marrow reserve
  • Poor organ function
  • Known intolerance to infused protein products, sucrose, histidine, polysorbate 80 or known hypersensitivity to any of the components of the study therapy that was not amenable to pre-medication with steroids and H2 blockers
  • Any serious active disease (including clinically significant infection that was chronic, recurrent, or active) or co-morbid condition, which, in the opinion of the investigator, interfered with the safety, the compliance with the study or with the interpretation of the results
  • Any severe underlying medical conditions including presence of laboratory abnormalities, which impaired the ability to participate in the study or the interpretation of its results
  • The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Источник: ClinicalTrials.gov, NCT01084252 · запись обновлена в реестре 1 ноября 2024.

Дизайн и результаты

ДизайнРандомизированное, открытое (без ослепления), параллельные группы; цель — лечение
Включено участников (факт, все страны)351
Что измеряют — первичные конечные точки (4), вторичных — 32
  • Phase 1: Number of Participants With Dose Limiting Toxicities (DLTs) — Day 1 of Cycle 1 up to Day 14 of Cycle 2
  • Phase 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — From Baseline up to 30 days after the last dose (maximum duration: 120 weeks )
  • Phase 2 Stage 1: Percentage of Participants With Overall Response (OR) According to International Myeloma Working Group (IMWG) Uniform Response Criteria — From the date of randomization until disease progression or death or data cut-off (maximum duration: 77 weeks for Stage 1a arms and 53 weeks for Stage 1b arm)
  • Phase 2 Stage 2: Percentage of Participants With Overall Response According to Updated IMWG Response Criteria — From the date of randomization to date of death from any cause (maximum duration: 97 weeks)

Цель исследования

Primary Objective:

Phase 1:

To determine the maximum tolerated dose (MTD)/maximum administered dose (MAD) of SAR650984 (Isatuximab).

Phase 2 (stage 1):

To evaluate the activity of single-agent Isatuximab at different doses/schedules and to select dose and regimen to further evaluate the overall response rate (ORR) of Isatuximab as single agent or in combination with dexamethasone.

Phase 2 (stage 2):

To evaluate the activity in terms of overall response rate (ORR) of Isatuximab at the selected dose/schedule from stage1, as single agent (ISA arm) and in combination with dexamethasone (ISAdex arm).

Secondary Objectives:

Phase 1:

* To characterize the global safety profile including cumulative toxicities.
* To evaluate the pharmacokinetic (PK) profile of Isatuximab in the proposed dosing schedule(s).
* To assess the pharmacodynamics (PD), immune response, and preliminary disease response.

Phase 2 (stage 1): to evaluate the following objectives for Isatuximab as single agent:

* Safety
* Efficacy as measured by duration of response, clinical benefit rate, progression free survival, overall survival.

Phase 2 (stage 2): to evaluate the following objectives in each arm (ISA and ISAdex):

* Safety
* Efficacy as measured by duration of response, clinical benefit rate, progression free survival, overall survival.
* Participant-reported changes in health-related quality of life, symptoms of multiple myeloma and generic health status.
* Pharmacokinetic profile of Isatuximab.
* Immunogenicity of Isatuximab.
* Investigate the relationship between CD38 receptor density and CD38 receptor occupancy (Stage 1 only) on multiple myeloma cells and parameters of clinical response.

Области и заболевания

Где проходит

4 центра в 4 городах

Откуда эта информация

Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.

Изменения не сохранены

На этой странице есть несохранённые изменения. Если уйти со страницы, они пропадут.